S. Bar‐Yehuda - Concepedia

Author

S. Bar‐Yehuda

Tel Aviv University

Also Known As

P. Fishman, S Bar-Yehuda, S. Bar-Yehuda, S. Bar‐Yehuda, Shahar Bar-Yehuda, Shahar Bar–Yehuda

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Tel Aviv University Can-Fite BioPharma (Israel)Rabin Medical Center Bar-Ilan University Temple University

About

S. Bar‐Yehuda is an author at Tel Aviv University specializing in medicine, autoimmune disease, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	490
2	Immunology	3	3	327
3	Cell Biology	2	2	163
4	Cellular Physiology	2	2	163
5	Health Sciences	1	1	71

S. Bar‐Yehuda

Publications

941

Citations

H-Index

Page 1

	Year	Citations
Immune dysregulation to Ethiopian immigrants in Israel: relevance to helminth infections? Zvi Bentwich, Ziva Weisman, C. Moroz, Clinical & Experimental Immunology ImmunodeficienciesMalariaImmunologyImmune RegulationImmunodominance	1996	142
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment S. Bar‐Yehuda, Lea Rath‐Wolfson, Luis Del Valle, Arthritis & Rheumatism	2009	124
The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease Avivit Ochaion, S. Bar‐Yehuda, Shira Cohen, Cellular Immunology InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune Disease	2009	117
Adenosine acts as an inhibitor of lymphoma cell growth Pnina Fishman, S. Bar‐Yehuda, Gil Ohana, European Journal of Cancer Cancer ResearchMalignant DiseaseCell ProliferationMedicineCell Biology	2000	92
Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101 Gil Ohana, S. Bar‐Yehuda, Arie Arich, British Journal of Cancer	2003	91
CF102 an A<sub>3</sub> adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver Shira Cohen, Salomon M. Stemmer, G. Zozulya, Journal of Cellular Physiology	2010	80
Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. P. Fishman, S. Bar‐Yehuda, L Vagman PubMed Melanoma Cell LinesCancer ResearchOncologyMedicinePhysiology	1998	71
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats Avivit Ochaion, S. Bar‐Yehuda, Shira Cohen, Biochemical Pharmacology InflammationRheumatologyAdjuvant-induced Arthritis RatsAnti-inflammatoryRheumatoid Disorder	2008	68
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men A.-R. van Troostenburg, Elizabeth V. Clark, Wayne Carey, International Journal of Clinical Pharmacology and Therapeutics	2004	64
IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Lea Rath‐Wolfson, S. Bar‐Yehuda, Lea Madi, PubMed	2006	62

Page 1